Skip to content

Comparison between Bupivacaine 0.5% and Ropivacaine 0.75% for Spinal Anesthesia in Children

Comparative Study Between Hyperbaric Preparation of Bupivacaine 0.5% and Ropivacaine 0.75% for Subarachnoid Block in Pediatric Population.

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/09/045624
Enrollment
62
Registered
2022-09-19
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Subarachnoid Block: SUBARACHNOID BLOCK(Spinal Anaesthesia)GIVEN TO PEDIATRIC PATIENTS UNDERGOING INFRAUMBLICAL SURGERIES IN AGE GROUP 1 YEAR TO 10 YEARS GIVEN WITH BUPIVACAINE HEAVY 0.5

Sponsors

BHARATI HOSPITAL PUNE
Lead Sponsor
NEON LABORATORIES LIMITED
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1.American Society of Anaesthesiologists (ASA) Grade I & II patients, of both sexes. 2.Patients undergoing elective infraumblical surgery 3.Patients in the age group of 1-10 years.

Exclusion criteria

Exclusion criteria: 1. Patient or parental refusal 2. Infection at the site of injection. 3. Hemodynamic instability. 4. Pre existing neurological deficit.

Design outcomes

Primary

MeasureTime frame
ROPIVACAINE PROVIDES GOOD SURGICAL ANESTHESIA AND POST OPERATIVE ANALGESIA WITH LESS MOTOR BLOCKADETimepoint: 0 minFROM TIME OF SUBARACHNOID BLOCK WITH EITHER DRUG FOLLOWED BY 1 MIN,2 MIN,5 MIN,10 MIN,15 MIN,30 MIN,45 MIN,60 MIN,75MIN,90 MIN

Secondary

MeasureTime frame
HEMODYNAMIC OR NEUROLOGICAL COMPLICATION IF ANYTimepoint: FROM 0 MIN POST SUBARACHNOID INJECTION OF EITHER BUPIVACAINE OR ROPVACAINE UPTO 24 HOURS POST SURGERY

Countries

India

Contacts

Public ContactDr Khulud Tandel

Bharati Vidyapeeth Medical College Pune

abhi6264@gmail.com9371107686

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026